BRIEF-Radiopharm Theranostics To Meet With U.S. FDA To Align On Pivotal Phase 3 Trial Design For Rad 101 In Diagnosis Of Brain Metastases

Radiopharm Theranostics Ltd RAD.AX:

• RADIOPHARM THERANOSTICS TO MEET WITH U.S. FDA TO ALIGN ON PIVOTAL PHASE 3 TRIAL DESIGN FOR RAD 101 IN DIAGNOSIS OF BRAIN METASTASES

• RADIOPHARM THERANOSTICS - RAD101 RECEIVES FDA FAST TRACK DESIGNATION FOR BRAIN METASTASES DIAGNOSIS

• RADIOPHARM THERANOSTICS - SCHEDULES END-OF-PHASE 2 FDA MEETING FOR RAD101 PHASE 3 TRIAL ON OCT 1, 2026

Source text: ID:nGNX7P6Yh

Further company coverage: RAD.AX